Brassmonke
New member
Couple question for the community:
#1
I'm sure many of you saw that the Biden Administration confirmed their expansion of export restrictions. https://www.reuters.com/technology/...chips-expand-curbs-more-countries-2023-10-17/
Given that NVDA worked around the initial rollout of the regulation by limiting interconnect of chips sent to China will the new performance based test stymie further shipments? If they only received the updated parameters of the restriction via letter in August it seems that a hardware based solution is off the table.
#2 Was it beneficial to NVDA to produce the H800 because of limited packaging capacity at TSMC?
#3 25% of data center revenue is at risk. Compound that with two customers representing 17% and 22% of Q2 2024 revenue and it seems as if there are potential threats to a sustainable revenue stream. Assuming the two big customers likely MSFT, AMZN,TSLA,AVGO, META. What is the total buildout anticipated for A100/H100 needed at the various megacaps and will the massive buying spree slow as their enterprise spend returns to normal in the coming year (i.e. not able to simply pivot 90% of enterprise spend towards AI APU/TPU)?
I suppose I'm reminded somewhat of the windfall that Pfizer or Moderna experienced followed by a slowly eroding Forward PE as earnings dry up to to demand shortfall and was curious what the big brains of the forum think.
#1
I'm sure many of you saw that the Biden Administration confirmed their expansion of export restrictions. https://www.reuters.com/technology/...chips-expand-curbs-more-countries-2023-10-17/
Given that NVDA worked around the initial rollout of the regulation by limiting interconnect of chips sent to China will the new performance based test stymie further shipments? If they only received the updated parameters of the restriction via letter in August it seems that a hardware based solution is off the table.
#2 Was it beneficial to NVDA to produce the H800 because of limited packaging capacity at TSMC?
#3 25% of data center revenue is at risk. Compound that with two customers representing 17% and 22% of Q2 2024 revenue and it seems as if there are potential threats to a sustainable revenue stream. Assuming the two big customers likely MSFT, AMZN,TSLA,AVGO, META. What is the total buildout anticipated for A100/H100 needed at the various megacaps and will the massive buying spree slow as their enterprise spend returns to normal in the coming year (i.e. not able to simply pivot 90% of enterprise spend towards AI APU/TPU)?
I suppose I'm reminded somewhat of the windfall that Pfizer or Moderna experienced followed by a slowly eroding Forward PE as earnings dry up to to demand shortfall and was curious what the big brains of the forum think.